Royalty Pharma plc (RPRX): Long-Term Debt
$8.95B
As of 2025-12-31
$8.96B
As of 2026-06-30
+7.9%
3-year compound annual growth
+9.0%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.95B | +17.6% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $7.61B | +24.1% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $6.14B | -13.8% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $7.12B | +0.3% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $7.10B | +22.0% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $5.82B | n/a | 2022-02-15, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 2025-12-31 | $8.95B | +17.6% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $828.97M | n/a |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $2.57B | +7.8% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $5.36B | -12.3% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $3.76B | -12.9% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $993.95M | +0.2% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $836.37M | n/a |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $339.88M | +189.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $1.81B | +44.6% |
Compare RPRX, SRPT, AMRX, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗